PDF

Archivos suplementarios

pagina titulo y autores

Palabras clave

Kounis
Vasoespasmo
Anafilaxia
Cefditoreno

Cómo citar

1.
Molina Montero R, Pintado MC, Fernandez A, Lujan J, Llorente B, Cambronero JA. Síndrome de Kounis Tras Administración de Cefditoreno. Rev Arg de Ter Int. [Internet]. 16 de diciembre de 2016 [citado 25 de julio de 2024];33(4). Disponible en: https://revista.sati.org.ar/index.php/MI/article/view/446

Resumen

 Resumen

El síndrome de Kounis fue definido, por primera vez, en 1991, como la aparición simultánea de episodios coronarios agudos y reacciones alérgicas anafilácticas o anafilactoides. Los agentes etiológicos asociados a su aparición son múltiples y los más frecuentes son los fármacos, en especial, los antibióticos. Su diagnóstico es eminentemente clínico, no existe ninguna prueba patognomónica. No hay consenso ni guías de práctica clínica específicas; se recomienda el tratamiento específico para el síndrome coronario agudo enfocado en tratar el vasoespasmo y la anafilaxia, con el agravante de que puede haber contraindicaciones cuando se usan conjuntamente y que dichos fármacos antianginosos pueden desencadenar el cuadro.
Se presenta un caso clínico de síndrome de Kounis asociado a cefditorén, el primero descrito en la literatura.

Abstract

Kounis syndrome was first described in 1991 as the simultaneous occurrence of acute coronary events and allergic anaphylactic or anaphylactoid reactions.
Multiple etiologic agents are associated with this syndrome, the most common are drugs, especially antibiotics. Diagnosis is eminently clinical, there are not pathognomonic tests. Consensus and specific clinical practice guidelines are lacking; specific acute coronary syndrome treatment is recommended focusing on vasospasm and anaphylaxis, with the aggravating circumstance that contraindications can be present when used together and such antianginal drugs may trigger the condition.
We present a case of Kounis syndrome associated with cefditoren, the first reported in the literature.

 

PDF

Citas

<p class="MsoNormal"><span style="font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: ES-TRAD;" lang="ES-TRAD">Bibliograf&iacute;a:</span></p><p class="MsoListParagraphCxSpFirst"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; mso-list: l0 level1 lfo1;"><!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Arial; mso-ansi-language: EN-US;" lang="EN-US">1.<span style="font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">Kounis NG, Zavras GM. Histamine- induced coronary artery spam: the </span></p><p class="MsoListParagraphCxSpMiddle"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraphCxSpLast"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">concept of allergic angina. BR J ClinPract. 1991;45:121-8.</span></p><p class="MsoNormal" style="margin-left: 18.0pt;"><span style="font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">&nbsp;</span></p><p class="MsoListParagraph" style="text-indent: -18.0pt; mso-list: l0 level1 lfo1;"><!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Arial;">2.<span style="font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Rico P, Palencia E, Rodriguez-Aguirregabiria M.M. S&iacute;ndrome de Kounis. </span></p><p class="MsoNormal" style="margin-left: 18.0pt;"><span style="font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">&nbsp;</span></p><p class="MsoNormal" style="margin-left: 18.0pt;"><span style="font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Med Intensiva. 2012;36(5):358-364.</span></p><p class="MsoListParagraphCxSpFirst"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">&nbsp;</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; mso-list: l0 level1 lfo1;"><!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Arial;">3.<span style="font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Pamp&iacute;n F, Rial M, V&aacute;zquez R, Gonz&aacute;lez LA. S&iacute;ndrome coronario agudo </span></p><p class="MsoListParagraphCxSpLast"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">&nbsp;</span></p><p class="MsoNormal" style="margin-left: 18.0pt;"><span style="font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">por hipersensibilidad: S&iacute;ndrome de Kounis. Galicia Clin 2014;75(1):31-32.</span></p><p class="MsoListParagraph"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">&nbsp;</span></p><p class="MsoNormal" style="margin-left: 18.0pt;"><span style="font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">&nbsp;</span></p><p class="MsoListParagraphCxSpFirst" style="text-indent: -18.0pt; mso-list: l0 level1 lfo1;"><!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Arial; mso-ansi-language: EN-US;" lang="EN-US">4.<span style="font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">Kounis NG, Giannopoulos S, Soufras G, Kounis G, Goudevenos J. </span></p><p class="MsoListParagraphCxSpMiddle"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraphCxSpMiddle"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">Foods, drugs and environmental factors: Novel Kounis syndrome </span></p><p class="MsoListParagraphCxSpMiddle"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraphCxSpMiddle"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">offenders. Intern Med 54: 1577-1582, 2015.</span></p><p class="MsoListParagraphCxSpMiddle"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; mso-list: l0 level1 lfo1;"><!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Arial;">5.<span style="font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Baldom&aacute; N, Cosmen CR, Galinski SF, Garc&iacute;a LM, Gracia LR, Vill&eacute;n FE. </span></p><p class="MsoListParagraphCxSpMiddle"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">&nbsp;</span></p><p class="MsoListParagraphCxSpLast"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">Serum tryptase levels in acute coronary syndrones with ST elevation. Int </span></p><p class="MsoNormal" style="margin-left: 18.0pt;"><span style="font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraphCxSpFirst"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">J Cardiol. 2009; 131:403-4.</span></p><p class="MsoListParagraphCxSpMiddle"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; mso-list: l0 level1 lfo1;"><!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Arial; mso-ansi-language: EN-US;" lang="EN-US">6.<span style="font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">Lieberman P, Simons FE.</span><span style="font-size: 12pt; line-height: 115%; font-family: Arial, sans-serif;" lang="EN-US">Anaphylaxisand cardiovascular disease: </span></p><p class="MsoListParagraphCxSpLast"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoNormal" style="margin-left: 18.0pt;"><span style="font-family: Arial, sans-serif;" lang="EN-US">therapeutic dilemmas.ClinExp Allergy. 2015 Aug; 45(8): 1288-95.</span></p><p class="MsoListParagraphCxSpFirst"><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraphCxSpLast" style="text-indent: -18.0pt; mso-list: l0 level1 lfo1;"><!--[if !supportLists]--><span style="font-size: 12.0pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Arial; mso-ansi-language: EN-US;" lang="EN-US">7.<span style="font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 12pt; line-height: 115%; font-family: Arial, sans-serif;" lang="EN-US">Dogan V, Mert GO, Biteker FS, Mert KU, Biteker M. Treatment of Kounis </span></p><p class="MsoNormal" style="margin-left: 18.0pt;"><span style="font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US;" lang="EN-US">&nbsp;</span></p><p class="MsoListParagraph"><span style="font-size: 12pt; line-height: 115%; font-family: Arial, sans-serif;" lang="EN-US">syndrome. Int J Cardiol 2015; 181: 133-4. </span></p><p class="MsoNormal">&nbsp;</p><p class="MsoNormal"><span lang="EN-US">&nbsp;</span></p>

La revista no retiene los derechos de reproducción (copyright) por lo que los autores pueden volver a publicar sus trabajos con la sola mención a la fuente original de publicación.